Bitcoin price today: dips to $92k as Fed cut doubts spark risk-off mood
Sheila A. Denton, Executive Vice President and General Counsel at Incyte CORP (NASDAQ:INCY), sold 598 shares of common stock on November 4, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $101.36, for a total value of $60,613.
On the same day, Denton also exercised options to acquire 598 shares of Incyte common stock at a price of $58.06, for a total value of $34719.
In other recent news, Prelude Therapeutics announced an exclusive option agreement with Incyte for its JAK2V617F inhibitor program, securing $60 million in immediate capital. This includes a $35 million upfront payment and a $25 million strategic equity investment, with potential future payments if Incyte exercises its option to acquire the program. Incyte’s agreement with Prelude highlights its strategic interest in expanding its oncology portfolio. Additionally, Incyte received a stock upgrade from Guggenheim, moving from Neutral to Buy, with a new price target of $125. This upgrade is linked to promising data from Incyte’s oncology programs, set to be showcased at an upcoming conference. Furthermore, TD Cowen raised its price target for Incyte to $101, citing a strong third-quarter performance and raised guidance for its Jakafi and other oncology products. Oppenheimer also increased its price target for Incyte to $84, following impressive quarterly results that surpassed revenue estimates. These developments reflect Incyte’s positive momentum in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.